WHO Prequalifies India-Made Novel Oral Polio Vaccine (nOPV2) | 16 Feb 2026

Why in News?

The World Health Organization prequalified a novel oral polio vaccine type 2 (nOPV2),a breakthrough in stopping polio outbreaks more sustainably with stronger global vaccine supply. 

Key Points: 

• Manufacturing: This milestone is particularly significant for India as the vaccine is manufactured by Biological E. Limited (BioE), a Hyderabad-based company.  
• Boost Health Security: Approval serves as a critical boost to both national health security and India's role in the global eradication campaign.  
• nOPV2 as a "Game-Changer":The primary challenge in current polio eradication is Circulating Vaccine-Derived Poliovirus (cVDPV2)—outbreaks caused when the weakened virus in traditional oral vaccines mutations back into a virulent form in under-immunized communities.  
• Superior Stability: nOPV2 is engineered to be more genetically stable, reducing the risk of reverting to a form that causes paralysis by approximately 80% compared to traditional vaccines. 
• Massive Production Capacity: Biological E. is expected to produce 600 million doses annually, significantly diversifying the global supply beyond the original manufacturer in Indonesia. 
• Flexible Logistics: The vaccine has a 24-month shelf life and can be stored at standard temperatures for up to six months, making it easier to deploy in remote areas. 
• World Polio Day: It is observed every year on 24th October in order to call on countries to stay vigilant in their fight against the disease